Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc., a Nevada corporation, on November 12, 2024. The filing serves to disseminate financial information regarding the quarter ended September 30, 2024, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly references a press release (Exhibit 99.1) for these details but does not include the data within the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document acts solely as a notification that financial results for the quarter ended September 30, 2024, have been issued.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, outlook, or risk factors are enumerated in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2024) for actual financial figures for the quarter ended September 30, 2024.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (TOVX) and exchange (NYSE American) for the common stock.
- Note that the financial data in this 8-K is not subject to the liabilities of Section 18 of the Exchange Act.